US Pharma MarketingThe post First patient receives Forzinity in Mighty Therapeutics’ Phase IV study appeared first on Clinical Trials Arena.
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity injection in those aged at least five years with Barth syndrome. The 4TAZPower study will follow participants with Barth syndrome for 72 weeks to assess the efficacy and safety. The trial aims to provide additional data to confirm clinical benefit and better understand the long-term safety profile of the treatment. Credit: Stock-Asso / Shutterstock.com. Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity (elamipretide) injection in those aged at least five years with Barth syndrome.…
Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity injection in those aged at least five years with Barth syndrome.
Source: Clinical Trials Arena